Back to Search
Start Over
Additional file 2: Table S2. of Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study
- Publication Year :
- 2017
- Publisher :
- Figshare, 2017.
-
Abstract
- Most common TEAEs per 100 patient-years of exposure to vismodegib. TEAEs by type during vismodegib treatment for 1Â year and after 12Â monthsâ treatment. (DOCX 14Â kb)
Details
- Database :
- OpenAIRE
- Accession number :
- edsair.doi...........f5a6219c03743040d2f5584232f4083b
- Full Text :
- https://doi.org/10.6084/m9.figshare.c.3781307_d2.v1